Max Healthcare Institute Limited

rs,

a Complex, Bandra (E), Mumbai – 400 051 Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Symbol: MAXHEALTH Scrip Code: 543220 Sub.: Presentation for In

77%

1 0 4 Sec. 43 Gurugram Lajpat Nagar3,4 5 0 0 Noida3,4 2 0 0 Bulandshahr Smart 22 Facilities 77% Beds in metros ~74% FY25 Occupancy7 24% Revenue CAGR6 4 years 38% EBITDA CAGR6 4 years 35% FY25

74%

m Lajpat Nagar3,4 5 0 0 Noida3,4 2 0 0 Bulandshahr Smart 22 Facilities 77% Beds in metros ~74% FY25 Occupancy7 24% Revenue CAGR6 4 years 38% EBITDA CAGR6 4 years 35% FY25 ROCE7 Outside NCR

24%

5 0 0 Noida3,4 2 0 0 Bulandshahr Smart 22 Facilities 77% Beds in metros ~74% FY25 Occupancy7 24% Revenue CAGR6 4 years 38% EBITDA CAGR6 4 years 35% FY25 ROCE7 Outside NCR 3 4 3 2 1 9 Lucknow

rs 38

Bulandshahr Smart 22 Facilities 77% Beds in metros ~74% FY25 Occupancy7 24% Revenue CAGR6 4 years 38% EBITDA CAGR6 4 years 35% FY25 ROCE7 Outside NCR 3 4 3 2 1 9 Lucknow Dehradun 2 2 0 2 0 0

rs 35

ilities 77% Beds in metros ~74% FY25 Occupancy7 24% Revenue CAGR6 4 years 38% EBITDA CAGR6 4 years 35% FY25 ROCE7 Outside NCR 3 4 3 2 1 9 Lucknow Dehradun 2 2 0 2 0 0 Mohali3,4 Bathinda 3 2 8

4.0%

Mohali3,4 Bathinda 3 2 8 2 1 2 Mumbai Nagpur Shareholding structure (as on March 31, 2025) 4.0% 17.6% 23.7% 54.7% Abhay Soi FIIs & FPIs DIIs Others Top public shareholders • Capital Group

17.6%

li3,4 Bathinda 3 2 8 2 1 2 Mumbai Nagpur Shareholding structure (as on March 31, 2025) 4.0% 17.6% 23.7% 54.7% Abhay Soi FIIs & FPIs DIIs Others Top public shareholders • Capital Group • GIC

23.7%

Bathinda 3 2 8 2 1 2 Mumbai Nagpur Shareholding structure (as on March 31, 2025) 4.0% 17.6% 23.7% 54.7% Abhay Soi FIIs & FPIs DIIs Others Top public shareholders • Capital Group • GIC • Black

54.7%

a 3 2 8 2 1 2 Mumbai Nagpur Shareholding structure (as on March 31, 2025) 4.0% 17.6% 23.7% 54.7% Abhay Soi FIIs & FPIs DIIs Others Top public shareholders • Capital Group • GIC • Blackrock /

₹ 1.1 lakh

anguard • Fidelity Investments • Wasatch Advisors • HDFC Mutual Fund • SBI Mutual Fund Market Cap: ₹ 1.1 lakh Cr / $ 12.5 billion 1. Market cap as of March 31, 2025 | 2. Based on publicly available informatio

12.5 billion

Investments • Wasatch Advisors • HDFC Mutual Fund • SBI Mutual Fund Market Cap: ₹ 1.1 lakh Cr / $ 12.5 billion 1. Market cap as of March 31, 2025 | 2. Based on publicly available information for listed compani

“Provision for NPV of the amount payable by a PHF to unconsolidated part of other Society over the contract period was accrued at the time of PPA & payment made in Q3 FY25 against such liability has been knocked off against such provision.”

“Pertains to VRS payout to employees in FY22 of ₹ 9 Cr and charges paid to YEIDA for seeking permission for change in shareholding of JHL of ₹ 74 Cr in FY25 4.”

“Excludes gain on reversal of deferred tax liability of ₹ 244 Cr (net) in FY23 and ₹ 18 Cr (net) in FY25 pursuant to voluntary liquidation of a step down subsidiaries and distribution of its assets to their immediate holding company 29 Network balance sheet1 (Includes Managed and Partner Healthcare Facilities) Mar 20247 Particulars 9,295 1,177 461 87 173 37 Shareholders' Equity (incl.”

Less

2

Contact

1

Less

ESOP (Equity-settled Scheme) Movement in fair value of contingent consideration payable & amortisation of contract assets Reported EBITDA Finance costs (net) Depreciation & Amortisation Profit before tax Exceptional item Profit before tax after Exceptional item Tax Profit after tax Note: New PHFs i.e. Vikrant Foundation and Nirogi Trust have not been reflected separately and included in the Eliminations & Adjustments due to negligible values. Eliminations & adjustments are restricted to direct costs and intra-network eliminations unlike previous year 1. Mainly accounting for leases at PHFs | 2. Eliminations relate to revenue from PHFs and intra-network sale/purchase. Also includes consequential impact on amortization due to reversal of intangible assets recognized at MHIL & its subsidiaries for contracts with PHFs. Provision for NPV of the amount payable by a PHF to unconsolidated part of other Society over the contract period was accrued at the time of PPA & payment made in Q3 FY25 ag

Less

ESOP (Equity-settled scheme) Movement in fair value of contingent consideration payable and amortisation of contract assets2 34 7 0.7% 0.1% 34 4 0.6% 0.1% 50 17 Reported EBITDA Finance costs (net) Depreciation and amortisation Profit before tax Exceptional item3 Profit before tax after Exceptional item Tax4 Profit after tax 1,349 25.7% 1,597 27.1% 1,840 112 248 989 9 979 143 837 2.2% 4.8% 18.8% 0.2% 18.8% 2.7% 16.0% 39 260 0.7% 4.4% (38) 284 1,298 22.0% 1,594 - 1,298 214 1,084 - 22.0% 3.6% 18.4% - 1,594 316 1,278 0.7% 0.3% 26.9% (0.5%) 4.2% 23.3% - 23.3% 4.6% 18.7% 55 25 0.6% 0.3% 2,239 25.8% 84 406 1,748 74 1,675 357 1,318 1.0% 4.7% 20.2% 0.8% 19.3% 4.1% 15.2% Note: The numbers for the previous periods have been re-casted and re-grouped to make them comparable with the disclosures in the current period 1. FY22 includes gross revenue of ₹ 236 Cr and EBITDA of ₹ 85 Cr from Covid-19 vaccination & related antibody tests compared to ₹ 2 Cr revenues in FY23 2. Non-cash item represents the c

Contact

Aakrati Porwal Max Healthcare Institute Ltd. Tel: +91 9920 409393 Email: aakrati.porwal@maxhealthcare.com Anoop Poojari / Suraj Digawalekar CDR India Tel: +91 98330 90434 / 98211 94418 Email: anoop@cdr-india.com / suraj@cdr-india.com 44